EL7.AI
StocksMedium•16 November 2026•
3 min read

Bunzl starts second £250 million tranche of share buyback programme

Key Facts

1Bunzl started the second tranche with a cap of £250 million and a maximum of 23,045,802 shares.
2The company set 22 December 2026 as the latest date for completing the second tranche.
3Bunzl announced a share buyback programme of up to £500 million on 1 September 2026.
4Group revenue grew 3.1% at constant exchange rates in the third quarter of 2026.

Bunzl started the second tranche of its share buyback programme on 16 November, with a cap of £250 million and a maximum of 23,045,802 shares, according to the company’s announcement published via Investegate. The tranche is part of a programme worth up to £500 million in total, announced by the company on 1 September. Bunzl set 22 December as the latest date for completing the new tranche. Purchases are being made under an irrevocable, non-discretionary agreement with Goldman Sachs, acting as principal and bearing the risk. The announcement sets a defined timeframe and scale for returning capital as the company balances cash distributions with funding bolt-on acquisitions.

The programme announced in September was divided into tranches; the company set a cap of £250 million and a maximum of 32,421,142 shares for the first tranche. That tranche began on 1 September, with a deadline of 22 December 2026 for completion. In an update issued on 20 October, Bunzl said it had completed about £225 million of the programme. This means the company had disclosed that most of the first tranche’s value had been executed before announcing the start of the second tranche, while the programme’s overall limit remained at £500 million. The second tranche differs in its maximum number of shares, allowing the purchase of up to 23,045,802 shares against a similar financial cap of £250 million.

The company said its policy is to distribute surplus cash while retaining financial headroom for high-return bolt-on acquisitions. It also described the purpose of the buyback as reducing issued share capital. This approach places returns to shareholders within its capital allocation policy, while retaining the capacity to fund additional deals. In October, Bunzl announced the completion of its acquisition of Blueleaf Care in the UK. It said Blueleaf generated revenue of £58 million in 2025, providing practical context for the group’s decision to retain headroom for bolt-on acquisitions.

In the latest trading indicators included in its third-quarter update, group revenue rose 3.1% at constant exchange rates in the three months ended 30 September 2026. Underlying revenue increased 3.7% over the same period, while acquisitions contributed 0.4% to revenue growth. By contrast, fewer trading days reduced growth by 1.1 percentage points. Bunzl attributed underlying revenue growth to inflation linked to higher year-on-year product costs and to volume growth. It said volume growth continued to receive support from strong performance in its North American distribution business.

In its 20 October update, Bunzl maintained its 2026 outlook, expecting modest underlying revenue growth and a broadly stable operating margin year on year. The company compares this outlook with an operating margin of 7.6% in 2025. This comes as it continues to carry out the buyback programme alongside its operations and bolt-on acquisitions. The company’s shares closed at 2892 pence on 13 November, compared with a close of 2900 pence in the previous session, on 12 November. Upcoming dates in the company’s calendar include a pre-close trading statement on 17 December 2026, followed by the announcement of results for the year ended 31 December 2026 on 1 March 2027.

Open on chart